Trial Profile

Phase Ib/II Study of IDH2 Inhibitor Enasidenib in Combination With BCL2 Inhibitor Venetoclax in Patients With IDH2-Mutated Myeloid Malignancies (ENAVEN-AML)

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 31 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enasidenib (Primary) ; Venetoclax (Primary)
Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
Focus Adverse reactions; Therapeutic Use
Acronyms ENAVEN-AML

Most Recent Events

23 Jan 2024 Status changed from active, no longer recruiting to discontinued (due to insufficient funding).
12 Dec 2023 Final results (data cutoff date: 30 Jun 2023) reporting safety and efficacy data with a median follow-up of over 17 months presented at the 65th American Society of Hematology Annual Meeting and Exposition
17 Jul 2023 Planned primary completion date changed from 1 Apr 2023 to 1 Jul 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com